SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-08-05
Accession Number: 0001641172-25-022123
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000164117225022123/filename1.htm

Chunk 4 of 82
Word Count: 1450
Character Count: 9303

Document Content:

we may be unable to market and sell our product candidates in certain jurisdictions. ● Our product candidates are subject to extensive regulatory requirements, including continuing regulatory review, which could affect the manufacturing and marketing of our product candidates. ● Our product candidates may be subject to extensive governmental regulation in foreign jurisdictions, such as the European Economic Area (EEA), and our failure to comply with applicable requirements could cause our business, results of operations and financial condition to suffer. ● The FDA regulatory approval, clearance and license process is complex, time-consuming and unpredictable. ● While BTD allows for increased interaction with FDA reviewers and prioritized submission review, it does not guarantee product approval, faster approval, or commercial success. Risks Related to Our Securities and this Offering active trading market for our common stock currently exists, and an active trading market may not develop or be sustained following this offering.

●	The
trading price of our common stock may be volatile, and you could lose all or part of your investment.

●	Certain
recent initial public offerings of companies with public floats comparable to our anticipated public float have experienced extreme
volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility,
which may make it difficult for prospective investors to assess the value of our common stock.

●	Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.

●	Our
management will have broad discretion in how we use the net proceeds from this offering and might not use them effectively.

●	You
will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

Implications
of Being an Emerging Growth Company

qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).
For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies. These provisions include, but are not limited to:

●	being
permitted to have only two years of audited financial statements and only two years of related management’s discussion and
analysis of financial condition and results of operations disclosure;

exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”);

●	reduced
disclosure about executive compensation arrangements in our periodic reports, registration statements, and proxy statements; and

●	exemptions
from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.

particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive
compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained
herein may be different from the information you receive from other public companies in which you hold stock.

addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies. We are not choosing to “opt out” of this provision. We will remain an
emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.235
billion, (ii) the date on which we first qualify as a large accelerated filer under the rules of the Securities and Exchange Commission
(the “SEC”), (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible
debt securities, and (iv) the last day of the fiscal year following the fifth anniversary of the completion of this offering.

Implications
of Being a Smaller Reporting Company

Following
this offering, we will be a “smaller
reporting company” as defined in Rule 12b-2 under the Exchange Act. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock
held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues
are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates
is less than $700 million measured on the last business day of our second fiscal quarter.

Corporate
Information

We are currently
a Delaware corporation. Our predecessor, CHF Technologies,
Inc., was incorporated under the laws of the State of California on October 15, 2003. On June 8, 2012, we incorporated BioVentrix, Inc.
under the laws of the State of Delaware, which subsequently merged into CHF Technologies, Inc., with BioVentrix, Inc. as the surviving
corporation in the merger. Our principal executive office is located at 120 Forbes Blvd., Suite 125, Mansfield, MA 02048. Our telephone
number is (925) 290-1000 and our website is www.bioventrix.com. Information contained on, or available through, our website
does not constitute part of, and is not deemed incorporated by reference into, this prospectus, and investors should not consider any
such information as part of this prospectus.

THE
OFFERING

Common
Stock Offered by Us shares
of common stock on a firm commitment basis (or shares of common stock if the underwriters exercise their over-allotment option in
full).

Common
Stock Outstanding Prior to This Offering 1 11,242,099
shares of common stock. This includes 5,529,454 shares of common stock being issued upon the closing of this offering in connection
with the conversion of: (i) 1,565,000 shares of our existing Series A Preferred Stock into 1,565,000 shares of common stock and (ii)
$5,827,000 of our existing convertible notes into 3,964,454 shares of our common stock.

Common
Stock to Be Outstanding Immediately After Completion of This Offering (1) shares
of common stock (or            shares of common stock if the underwriters
exercise their over-allotment option in full).

Over-allotment
Option We
have granted the underwriters a 30-day option to purchase up to an additional
shares of our common stock at the initial public offering price, less underwriting discounts and commissions, solely to cover over-allotments,
if any.

Use
of Proceeds We
estimate that the net proceeds to us from this offering, after deducting the underwriting
discounts and estimated offering expenses payable by us, will be approximately $
million, or approximately $          million
if the underwriters exercise their over-allotment option in full, based on the assumed initial
public offering price of $         per share.

The
net proceeds received by us from this offering will be used primarily to fund the RELIVE clinical trial and the associated manufacturing
activities required to support such trial. The remaining portion of the net proceeds will be used to fund working capital and general
and administrative expenses. See “ Use of Proceeds .”

Representative’s
Warrant The
registration statement of which this prospectus is a part also registers the offer and sale of a common stock purchase warrant to
be issued to the representative of the underwriters (the “Representative’s Warrant”) to purchase shares of
our common stock (or 5% of the shares of common stock sold in this offering), including any shares of common stock sold pursuant
to the exercise of the underwriters’ over-allotment option, and the shares of our common stock issuable upon exercise of the
Representative’s Warrant. The Representative’s Warrant is being issued to the representative of the underwriters as a
portion of the underwriting compensation payable in connection with this offering. The Representative’s Warrant is exercisable
at any time, and from time to time, in whole or in part, from the first day of the seventh month after the closing of this
offering, to the date that is five years from the date of commencement of sales in this offering, at an exercise price equal
to the initial public offering price of the shares of common stock. Please see “ Underwriting — Representative’s
Warrant ” for further information.

Listing We
intend to apply to have our common stock listed on Nasdaq. No assurance can be given that our listing will be approved by Nasdaq
or that a trading market will develop for our common stock. We will not proceed with this offering in the event that our common stock
is not approved for listing on Nasdaq.

Proposed
Nasdaq symbol “BVXX”

Risk
Factors Investing
in our common stock is speculative and involves a high degree of risk . See “ Risk Factors ” beginning on
page 9 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide
to invest in our common stock.